NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NPCE NeuroPace Inc.

Market Closed 01-09 16:00:00 EST

16.73

-0.23

-1.36%

盘后16.92

+0.19+1.16%

19:28 EST

High17.34	Low15.98	Vol374.72K
Open17.21	D1 Closing16.96	Amplitude8.02%
Mkt Cap553.45M	Tradable Cap376.80M	Total Shares33.08M
T/O6.23M	T/O Rate1.66%	Tradable Shares22.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NPCE","market":"US","secType":"STK","nameCN":"NeuroPace Inc.","latestPrice":16.73,"timestamp":1767992400000,"preClose":16.96,"halted":0,"volume":374719,"hourTrading":{"tag":"盘后","latestPrice":16.9245,"preClose":16.73,"latestTime":"19:28 EST","volume":2008,"amount":33863.014,"timestamp":1768004928741},"delay":0,"floatShares":22522505,"shares":33081498,"eps":-0.753018,"marketStatus":"Market Closed","change":-0.23,"latestTime":"01-09 16:00:00 EST","open":17.21,"high":17.34,"low":15.98,"amount":6231986.163148,"amplitude":0.080189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.753018,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"listingDate":1619064000000,"exchange":"NASDAQ","adjPreClose":16.96,"preHourTrading":{"tag":"盘前","latestPrice":17.29,"preClose":16.96,"latestTime":"09:28 EST","volume":805,"amount":13977.66097,"timestamp":1767968893156},"postHourTrading":{"tag":"盘后","latestPrice":16.9245,"preClose":16.73,"latestTime":"19:28 EST","volume":2008,"amount":33863.014,"timestamp":1768004928741},"volumeRatio":0.9335213068103827,"impliedVol":0.5693,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/NPCE","defaultTab":"news","newsList":[{"id":"2592899091","title":"NeuroPace Submits FDA Application to Expand RNS System Indication for Drug-Resistant Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592899091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592899091?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976453,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc. has filed a Premarket Approval Supplement  application with the U.S. Food and Drug Administration  seeking to expand the labeled indication for its RNS System to include patients with antiseizure-medication resistant idiopathic generalized epilepsy  with generalized tonic-clonic seizures. The submission is supported by positive preliminary 18-month data from the NAUTILUS clinical trial. The company aims to provide new treatment options for patients with drug-resistant IGE, who currently lack approved neuromodulation therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on December 17, 2025, and is solely responsible for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5xykKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2592990642","title":"Neuropace Files Pma Supplement to FDA Seeking Expanded Rns® System Indication for Idiopathic Generalized Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990642?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUAD8GPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","NPCE","BK4082"],"gpt_icon":0},{"id":"2591922935","title":"UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591922935","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591922935?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:50","pubTimestamp":1765900215,"startTime":"0","endTime":"0","summary":"NeuroPace (NPCE) has an average rating of Buy and mean price target of $19.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NPCE"],"gpt_icon":0},{"id":"2591168938","title":"NeuroPace Is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2591168938","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591168938?lang=en_us&edition=fundamental","pubTime":"2025-12-16 22:36","pubTimestamp":1765895760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 09:36 ET (14:36 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0},{"id":"2590848539","title":"NeuroPace Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590848539","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590848539?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:09","pubTimestamp":1765382940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 11:09 ET (16:09 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0},{"id":"2589666353","title":"Neuropace Inc - 77% Median Reduction in Gtc Seizures at 18 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2589666353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589666353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0V8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2589353667","title":"Neuropace: Remains on Track to Submit Nautilus Pma Supplement to FDA for Ige Indication Expansion by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353667?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0V8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NPCE","BK4539"],"gpt_icon":0},{"id":"2589353664","title":"Neuropace Announces Positive 18-Month Nautilus Trial Results in Idiopathic Generalized Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353664?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","NPCE","BK4082"],"gpt_icon":0},{"id":"2589353324","title":"NeuroPace Reports Positive 18-Month Results from NAUTILUS Trial for Drug-Resistant Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353324","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353324?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:01","pubTimestamp":1765198889,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc. has announced the presentation of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS clinical trial at the American Epilepsy Society  meeting. The NAUTILUS trial is evaluating the RNS System as an adjunctive therapy for the treatment of antiseizure medication-resistant idiopathic generalized epilepsy  with generalized tonic-clonic  seizures. The RNS System is a brain-responsive device designed to deliver real-time, personalized treatment at the seizure source. Further details regarding the trial can be found on the NeuroPace website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on December 08,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL86lQMy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NPCE","BK4539"],"gpt_icon":0},{"id":"2588053402","title":"Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053402","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053402?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680520,"startTime":"0","endTime":"0","summary":"NeuroPace Inc. has announced that new clinical data and advances related to its RNS System and AI-powered NeuroPace platform will be featured at the 2025 American Epilepsy Society  Annual Meeting in Atlanta, Georgia. The company will present new analyses from the RNS System Post-Approval Study , including long-term seizure reduction durability and quality-of-life outcomes in drug-resistant focal epilepsy populations. Preliminary 18-month safety and efficacy results from the NAUTILUS clinical trial, which evaluates responsive thalamic stimulation for idiopathic generalized epilepsy, will also be presented. In addition, NeuroPace will provide an initial overview of its next-generation AI and SeizureID tools, designed to enhance epilepsy care through advanced analysis of intracranial EEG data. These results and tools are scheduled to be presented at the upcoming AES 2025 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2z9Zcz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"gpt_icon":0},{"id":"2585149573","title":"BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149573","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585149573?lang=en_us&edition=fundamental","pubTime":"2025-11-24 23:52","pubTimestamp":1763999543,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, GencoEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL6N3X00OY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VG","LU0306807586.USD","TSCO","LU2237443549.SGD","CVNA","GNK","GDOT","FUN","LU0724618789.USD","CLSDQ","BLFY","CLSD","LU0788108826.HKD","EXAS","LU0278409577.USD","ELV","H","HUM","NPCE","LU0211331839.USD","NNOX","BK4547","LU0528227936.USD","LU1244550494.USD","LU2237443622.USD","ALHC","MS","CDE","MRK","BIIB","BK4115","LU0496367417.USD","NRSN","IE00BMPRXN33.USD","LU1032466523.USD","BMY","KSS","IVVD","GB00BDT5M118.USD","HL","OOMA","IE000M9KFDE8.USD","PANW"],"gpt_icon":1},{"id":"2585030460","title":"BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=2585030460","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585030460?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:19","pubTimestamp":1763993963,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP MaterialsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL6N3X00F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU0061474960.USD","LU0143863784.USD","LU2097828714.EUR","LU0708995153.HKD","LU0985489474.SGD","BIIB","LU0164865239.USD","CLSD","CVNA","LU0417516738.SGD","LU1804176565.USD","MNSH","LU0593848301.USD","LU0307460666.USD","ALBmain","LU0029874905.USD","PANW","GDOT","HUM","ALHC","LU0306807586.USD","IVVD","BK4007","MP","ELV","LU1267930227.SGD","89988","AU","BMY","CLSDQ","LU1803068623.USD","FUN","HBBD.SI","LU0328353924.USD","IE00B19Z9505.USD","NPCE","LU0441854154.USD","TSCO","EXAS","OOMA","DDOG","VG"],"gpt_icon":1},{"id":"2585460895","title":"NeuroPace (NPCE) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585460895?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:55","pubTimestamp":1763992540,"startTime":"0","endTime":"0","summary":"Lake Street analyst Frank Takkinen reiterated a Buy rating on NeuroPace today and set a price target of $20.00. Takkinen covers the Healthcare sect...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neuropace-npce-gets-a-buy-from-lake-street-blurbs-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neuropace-npce-gets-a-buy-from-lake-street-blurbs-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4539","BK4588","XBI","XLV","NPCE","BK4082","BK4581","LABU"],"gpt_icon":0},{"id":"2585485467","title":"BUZZ-NeuroPace jumps as Medicare boosts pay for epilepsy device procedures","url":"https://stock-news.laohu8.com/highlight/detail?id=2585485467","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585485467?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:45","pubTimestamp":1763991926,"startTime":"0","endTime":"0","summary":"BUZZ-NeuroPace jumps as Medicare boosts pay for epilepsy device procedures** Shares of medical device maker Neuropace NPCE.O rise 2.1% to $14.65 premarket** Co says Medicare will increase payments for its RNS System, a device used to treat drug-resistant epilepsy** Under new rules for 2026, the Centers for Medicare & Medicaid Services or CMS, will raise payments to doctors who implant or replace the RNS System by about 43% for initial procedures and 45% for replacements - NPCE** CMS also moves RNS replacement to highest-paying outpatient category, lifting hospital reimbursement by 47% to $31,526 - NPCE** Co expects the higher payments to support growth in both physician use and hospital access for Medicare patients** Up to last close, stock up ~28% YTD   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL4N3X00OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"gpt_icon":0},{"id":"2585467131","title":"NeuroPace Says Medicare Increases Reimbursement for RNS Procedures","url":"https://stock-news.laohu8.com/highlight/detail?id=2585467131","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585467131?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:42","pubTimestamp":1763991722,"startTime":"0","endTime":"0","summary":"NeuroPace  said Monday that Medicare reimbursement will \"substantially increase\" for its RNS neurostimulator implant and replacement procedures.The physician fee schedule for 2026 increases professional payment for neurosurgeons by about 43% for the initial implant and 45% for replacement procedures, the company said.Separately, the outpatient prospective payment system final rule increases average hospital medicare reimbursement by 47% starting Jan. 1, 2026.Shares of NeuroPace were up by 2% in recent Monday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","NPCE","BK4082"],"gpt_icon":0},{"id":"2585462521","title":"Neuropace Inc - Payment Rates Increased by Approximately 43% (+$530) for Initial Implant Procedure, 45% (+$260) for Replacement Procedure","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462521?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:02","pubTimestamp":1763989323,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00JK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NPCE","BK4539"],"gpt_icon":0},{"id":"2585346252","title":"Neuropace Inc - Announces Favorable Medicare Reimbursement Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2585346252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585346252?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:02","pubTimestamp":1763989323,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2585515203","title":"3 Stocks Possibly Trading At A Discount Of Up To 37.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585515203","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585515203?lang=en_us&edition=fundamental","pubTime":"2025-11-21 01:08","pubTimestamp":1763658493,"startTime":"0","endTime":"0","summary":"In the current U.S. market landscape, major stock indexes have recently experienced fluctuations, with notable gains following Nvidia's impressive earnings results and Walmart's strong performance. Amidst these developments, investors may find opportunities in stocks that are potentially trading below their intrinsic value, offering a chance to capitalize on market inefficiencies and economic shifts.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/7013000-choice2-main-header/1585186648241","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7013000-choice2-main-header/1585186648241"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/banks/nyse-mcb/metropolitan-bank-holding/news/3-stocks-possibly-trading-at-a-discount-of-up-to-378","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/banks/nyse-mcb/metropolitan-bank-holding/news/3-stocks-possibly-trading-at-a-discount-of-up-to-378","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TOWN","BK4023","BK4198","BK4104","BK4211","BK4082","BK4588","BK7095","BK4548","BK7078","BILL.AU","BK4585","CAI","BK4195","NPCE","BILL","LU2264538146.SGD","MCB","BK4551","CAI.AU","PERF","LU1988902786.USD","BK4139","HAS.AU","BCBP","BK7104","BK4539","STAA","HAS","HBNC","NWBI","CROX","BK4146","BBT.AU","BK4535","LU1064131342.USD","BK4566","BBT","BK4190"],"gpt_icon":0},{"id":"2581705337","title":"NeuroPace Up Over 40%, On Pace for Record Percent Increase -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581705337","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581705337?lang=en_us&edition=fundamental","pubTime":"2025-11-06 01:32","pubTimestamp":1762363920,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc.  is currently at $13.16, up $3.76 or 40.05%. --Would be highest close since June 5, 2025, when it closed at $13.28. --Up 17.65% year-to-date; on pace for best year since 2023, when it rose 591.95%. --Down 50.32% from its all-time closing high of $26.50 on April 27, 2021. --Up 68.78% from 52 weeks ago , when it closed at $7.80. --Down 27.39% from its 52-week closing high of $18.13 on May 21, 2025. --Up 84.38% from its 52-week closing low of $7.14 on Nov. 12, 2024. --Traded as high as $13.25; highest intraday level since June 9, 2025, when it hit $13.37. --Up 40.96% at today's intraday high; largest intraday percent increase since Aug. 9, 2023, when it rose as much as 57.32%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2581771571","title":"NeuroPace Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2581771571","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581771571?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:27","pubTimestamp":1762356420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 10:27 ET (15:27 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuropace.com","stockEarnings":[{"period":"1week","weight":0.1028},{"period":"1month","weight":-0.003},{"period":"3month","weight":0.6274},{"period":"6month","weight":0.7574},{"period":"1year","weight":0.393},{"period":"ytd","weight":0.0835}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.53436},{"month":2,"riseRate":0.5,"avgChangeRate":0.027762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.069398},{"month":4,"riseRate":0.25,"avgChangeRate":-0.001962},{"month":5,"riseRate":0.2,"avgChangeRate":-0.144641},{"month":6,"riseRate":0.6,"avgChangeRate":-0.044447},{"month":7,"riseRate":0.4,"avgChangeRate":-0.04203},{"month":8,"riseRate":0.6,"avgChangeRate":0.216975},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065676},{"month":10,"riseRate":0,"avgChangeRate":-0.132059},{"month":11,"riseRate":0.6,"avgChangeRate":0.163487},{"month":12,"riseRate":0.6,"avgChangeRate":0.015944}],"exchange":"NASDAQ","name":"NeuroPace Inc.","nameEN":"NeuroPace Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuroPace Inc.,NPCE,NeuroPace Inc.股票,NeuroPace Inc.股票老虎,NeuroPace Inc.股票老虎国际,NeuroPace Inc.行情,NeuroPace Inc.股票行情,NeuroPace Inc.股价,NeuroPace Inc.股市,NeuroPace Inc.股票价格,NeuroPace Inc.股票交易,NeuroPace Inc.股票购买,NeuroPace Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction